[New development of diagnosis and treatment for Parkinson's disease]

Rinsho Shinkeigaku. 2017 Jun 28;57(6):259-273. doi: 10.5692/clinicalneurol.cn-000969. Epub 2017 May 26.
[Article in Japanese]

Abstract

New methods for the diagnosis and new treatments for Parkinson's disease (PD) were explained. As imaging tools, neuromelanin imaging using brain MRI, meta-iodobenzylguanidine (MIBG) cardiac scintigraphy, dopamine transporter scintigraphy, and transcranial sonography were introduced. Olfactory dysfunction and REM sleep behavior disorders (RBD), which are important non-motor symptoms, and the new Clinical Criteria for PD launched by Movement Disorder Society (MDS) were also described. Investigative new medications and new anti-PD medications, which recently became available in Japan, were introduced. I explained the rationale of early treatment, strategy of initial treatment, the significance of continuous dopaminergic stimulation, strategy of treatment for advanced PD, and deep brain stimulation as a surgical treatment together with promising new treatments including gene therapy and cell transplantation.

Keywords: MIBG cardiac scintigraphy; REM sleep behavior disorder; continuous dopaminergic stimulation; dopamine transporter scintigraphy; olfactory function.

Publication types

  • Review

MeSH terms

  • 3-Iodobenzylguanidine
  • Antiparkinson Agents*
  • Cell- and Tissue-Based Therapy*
  • Deep Brain Stimulation*
  • Dopamine Plasma Membrane Transport Proteins
  • Dopaminergic Neurons
  • Electric Stimulation Therapy*
  • Genetic Therapy*
  • Humans
  • Magnetic Resonance Imaging
  • Myocardial Perfusion Imaging
  • Neuroimaging
  • Olfaction Disorders
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / therapy*
  • REM Sleep Behavior Disorder
  • Radionuclide Imaging
  • Substantia Nigra / diagnostic imaging
  • Ultrasonography

Substances

  • Antiparkinson Agents
  • Dopamine Plasma Membrane Transport Proteins
  • 3-Iodobenzylguanidine